New model aims to Fine-Tune leukemia drug dosing, reduce side effects
NCT ID NCT07499349
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a computer model that predicts how the drug Erwinase behaves in the body of children and young adults with acute lymphoblastic leukemia (ALL). By analyzing data from about 475 patients, researchers hope to find the best doses to kill cancer cells while avoiding harmful side effects like high ammonia levels. The model will help doctors personalize treatment, but it is an early research step and not a new therapy itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Erwinase (asparaginase enzyme)
What this could lead to
If successful, this could lead to more precise dosing of Erwinase, improving treatment outcomes and reducing side effects like hyperammonemia in children and young adults with ALL.
What could go wrong
This is an observational modeling study, not a treatment trial. The model may not fully capture individual patient variability, and its benefits depend on future validation and implementation in clinical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aarhus University Hospital
RECRUITINGAarhus, Denmark